Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Beach

Showing results (291-300 of 320) with videos related to

Pageof 32
Sort By:
Ecancermedicalscience|January 26, 2012
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an updateL R Silverman, P Fenaux, G J Mufti, et al.
Ecancermedicalscience|January 26, 2012
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an updateP Fenaux, G J Mufti, E Hellström-Lindberg, et al.
Anesthesia and Analgesia|November 13, 2012
Reduction in intraoperative bacterial contamination of peripheral intravenous tubing through the use of a passive catheter care systemRandy W Loftus, Bryan S Brindeiro, David P Kispert, et al.
Frontiers in Physiology|October 12, 2020
<i>In silico</i> Comparison of Left Atrial Ablation Techniques That Target the Anatomical, Structural, and Electrical Substrates of Atrial FibrillationCaroline H Roney, Marianne L Beach, Arihant M Mehta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemiaPierre Fenaux, Ghulam J Mufti, Eva Hellström-Lindberg, et al.
Blood|January 7, 2022
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease statusGail J Roboz, Farhad Ravandi, Andrew H Wei, et al.
Blood Advances|December 21, 2021
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AMLAmer M Zeidan, Isaac Boss, C L Beach, et al.
American Journal of Hematology|January 19, 2023
Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trialAndrew H Wei, Hartmut Döhner, Hamid Sayar, et al.
Blood Advances|December 31, 2021
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromesAmer M Zeidan, Isaac Boss, C L Beach, et al.
Blood|August 12, 2022
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidineHartmut Döhner, Andrew H Wei, Gail J Roboz, et al.
Pageof 32

Showing results (291-300 of 320) with videos related to

Sort By:
Pageof 32
Ecancermedicalscience|January 26, 2012
The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an updateL R Silverman, P Fenaux, G J Mufti, et al.
Ecancermedicalscience|January 26, 2012
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an updateP Fenaux, G J Mufti, E Hellström-Lindberg, et al.
Anesthesia and Analgesia|November 13, 2012
Reduction in intraoperative bacterial contamination of peripheral intravenous tubing through the use of a passive catheter care systemRandy W Loftus, Bryan S Brindeiro, David P Kispert, et al.
Frontiers in Physiology|October 12, 2020
<i>In silico</i> Comparison of Left Atrial Ablation Techniques That Target the Anatomical, Structural, and Electrical Substrates of Atrial FibrillationCaroline H Roney, Marianne L Beach, Arihant M Mehta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 23, 2009
Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemiaPierre Fenaux, Ghulam J Mufti, Eva Hellström-Lindberg, et al.
Blood|January 7, 2022
Oral azacitidine prolongs survival of patients with AML in remission independently of measurable residual disease statusGail J Roboz, Farhad Ravandi, Andrew H Wei, et al.
Blood Advances|December 21, 2021
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AMLAmer M Zeidan, Isaac Boss, C L Beach, et al.
American Journal of Hematology|January 19, 2023
Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trialAndrew H Wei, Hartmut Döhner, Hamid Sayar, et al.
Blood Advances|December 31, 2021
A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromesAmer M Zeidan, Isaac Boss, C L Beach, et al.
Blood|August 12, 2022
Prognostic impact of NPM1 and FLT3 mutations in patients with AML in first remission treated with oral azacitidineHartmut Döhner, Andrew H Wei, Gail J Roboz, et al.
Pageof 32